SPTLC2 sirna

SPTLC2 siRNA (Human)

Cat. Num. AAA8236672

• Gene Names: SPTLC2; LCB2; SPT2; HSN1C; LCB2A; NSAN1C; hLCB2a
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: SPTLC2; SPTLC2 siRNA (Human); KIAA0526; LCB2; Serine palmitoyltransferase 2; Long chain base biosynthesis protein 2; LCB 2; Long chain base biosynthesis protein 2a; LCB2a; Serine-palmitoyl-CoA transferase 2; SPT 2; SPTLC2 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: SPTLC2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 562

• Applicable Applications for SPTLC2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SPTLC2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for SPTLC2 sirna

siRNA to inhibit SPTLC2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4758668
• NCBI GeneID: 9517
• NCBI Accession #: NP_004854.1
• NCBI GenBank Nucleotide #: NM_004863.3
• UniProt Accession #: O15270; Q16685
• Molecular Weight: 62,924 Da
• NCBI Official Full Name: serine palmitoyltransferase 2
• NCBI Official Synonym Full Names: serine palmitoyltransferase, long chain base subunit 2
• NCBI Official Symbol: SPTLC2
• NCBI Official Synonym Symbols: LCB2; SPT2; HSN1C; LCB2A; NSAN1C; hLCB2a
• NCBI Protein Information: serine palmitoyltransferase 2
• UniProt Protein Name: Serine palmitoyltransferase 2
• Protein Family: Serine palmitoyltransferase
• UniProt Gene Name: SPTLC2
• UniProt Synonym Gene Names: KIAA0526; LCB2; LCB 2; LCB2a; SPT 2
• UniProt Entry Name: SPTC2_HUMAN

NCBI Description

This gene encodes a long chain base subunit of serine palmitoyltransferase. Serine palmitoyltransferase, which consists of two different subunits, is the key enzyme in sphingolipid biosynthesis. It catalyzes the pyridoxal-5-prime-phosphate-dependent condensation of L-serine and palmitoyl-CoA to 3-oxosphinganine. Mutations in this gene were identified in patients with hereditary sensory neuropathy type I. [provided by RefSeq, Mar 2011]

Uniprot Description

SPTLC2: Serine palmitoyltransferase (SPT). The heterodimer formed with LCB1/SPTLC1 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2-SSSPTA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC2-SSSPTB complex displays a preference for C18-CoA substrate. Defects in SPTLC2 are the cause of hereditary sensory and autonomic neuropathy type 1C (HSAN1C). It is a form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by prominent sensory abnormalities with a variable degree of motor and autonomic dysfunction. The neurological phenotype is often complicated by severe infections, osteomyelitis, and amputations. HSAN1C symptoms include loss of touch and vibration in the feet, dysesthesia and severe panmodal sensory loss in the upper and lower limbs, distal lower limb sensory loss with ulceration and osteomyelitis, and distal muscle weakness. Belongs to the class-II pyridoxal-phosphate-dependent aminotransferase family.

Protein type: Transferase; Lipid Metabolism - sphingolipid; Membrane protein, integral; EC 2.3.1.50

Chromosomal Location of Human Ortholog: 14q24.3

Cellular Component: endoplasmic reticulum membrane; mitochondrion; integral to membrane

Molecular Function: serine C-palmitoyltransferase activity; pyridoxal phosphate binding

Biological Process: sphingolipid metabolic process; sphingolipid biosynthetic process; sphingosine biosynthetic process; ceramide biosynthetic process; sphinganine biosynthetic process; sphingomyelin biosynthetic process

Disease: Neuropathy, Hereditary Sensory And Autonomic, Type Ic